Renal Associates P. A. ·
Area of research
Nephrology · Nutrition and Dietetics
Research interest
Research interests include Parathyroid Disorders and Treatments, Dialysis and Renal Disease Management, Magnesium in Health and Disease, and Vitamin D Research Studies.
Dialysis Facility Closures in the US From 2018 to 2024: A Serial Cross-Sectional Study
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Effects of Bardoxolone Methyl in Alport Syndrome
Measuring Medication Use, Obstacles, and Knowledge in Individuals With Cirrhosis
Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome
Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic
Integrated Efficacy and Safety of Bardoxolone Methyl in CKD
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)
Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the <scp>EVOLVE</scp> trial
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial
Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study
A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD
Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes
Serum Calcification Propensity and Clinical Events in CKD
A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease
Abstract P063: Serum Calcification Propensity and Cardiovascular Disease Events Among Patients With Chronic Kidney Disease: the CRIC Study
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses
Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease
LB05RANDOMIZED TRIAL OF THE EFFECTS OF FERRIC CITRATE IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference